Table 4.
Multivariable models stratified by factors showing interactive effects with the FAIN.
| HR (95%CI) | ||||
|---|---|---|---|---|
| Model | Cases/events | FAIN, continuous | FAIN, per 1 SD (0.3) | P inter |
| Crude model, overall | 14,134/3,241 | 0.21 (0.18–0.24) | 0.59 (0.56–0.62) | - |
| Fully-adjusted modela, b, overall | 14,134/3,241 | 0.57 (0.47–0.68) | 0.83 (0.78–0.88) | - |
| Sex | 0.002 | |||
| Female | 6,666/1,130 | 0.40 (0.30–0.54) | 0.74 (0.67–0.81) | |
| Male | 7,468/2,111 | 0.70 (0.56–0.88) | 0.89 (0.82–0.96) | |
| Tumor stage | <0.001 | |||
| I | 1,863/216 | 0.86 (0.45–1.64) | 0.95 (0.77–1.18) | |
| II | 3,229/545 | 0.72 (0.46–1.13) | 0.90 (0.77–1.04) | |
| III | 5,645/1,154 | 0.49 (0.36–0.67) | 0.79 (0.71–0.87) | |
| IV | 3,397/1,326 | 0.57 (0.43–0.76) | 0.83 (0.75–0.91) | |
| Curative chemotherapy | 0.001 | |||
| No | 11,627/2,386 | 0.51 (0.41–0.64) | 0.80 (0.74–0.86) | |
| Yes | 2,507/855 | 0.69 (0.49–0.98) | 0.88 (0.78–0.99) | |
| Pre-albumin, mg/L | 0.006 | |||
| <200 | 5,745/1,658 | 0.63 (0.48–0.82) | 0.86 (0.78–0.94) | |
| ≥200 | 8,389/1,583 | 0.52 (0.40–0.67) | 0.80 (0.73–0.87) | |
| Cancer type | 0.044 | |||
| Lung | 3,231/1,225 | 0.47 (0.34–0.66) | 0.78 (0.69–0.87) | |
| Colorectum | 2,215/430 | 0.39 (0.23–0.64) | 0.73 (0.61–0.86) | |
| Breast | 2,204/143 | 0.90 (0.36–2.25) | 0.97 (0.71–1.31) | |
| Stomach | 1,497/450 | 0.97 (0.71–1.34) | 0.99 (0.89–1.10) | |
| Other | 4,987/993 | 0.53 (0.38–0.73) | 0.81 (0.73–0.90) | |
| PG–SGA category | 0.005 | |||
| A (0–1) | 3,460/489 | 0.59 (0.37–0.93) | 0.84 (0.72–0.98) | |
| B (2–8) | 7,615/1,757 | 0.48 (0.38–0.63) | 0.78 (0.72–0.85) | |
| C (≥9) | 3,023/995 | 0.83 (0.61–1.12) | 0.94 (0.85–1.04) | |
| KPS score | 0.013 | |||
| <80 | 1,535/459 | 0.76 (0.45–1.29) | 0.91 (0.76–1.09) | |
| ≥80 | 12,599/2,782 | 0.52 (0.43–0.64) | 0.80 (0.75–0.86) | |
| Global QOL score | 0.004 | |||
| <80 | 10,002/2,515 | 0.63 (0.51–0.77) | 0.86 (0.80–0.92) | |
| ≥80 | 4,132/726 | 0.39 (0.26–0.58) | 0.73 (0.64–0.83) | |
FAIN, the fat-age-inflammation index; HR (95%CI), hazard ratio (95% confidence interval); SD, standard deviation; Pinter, P for interaction; KPS, the Karnofsky Performance Status score; QOL, quality of life score by the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 scale.
Model is adjusted for the age at baseline (continuous), sex (reference = female), tumor stage (reference = I), radical surgery (reference = no), curative chemotherapy (reference = no), pre-albumin (continuous), handgrip strength (continuous), the Nutritional Risk Screening (NRS) 2002 (reference = <3), length of hospital stay (continuous), cancer type (reference = lung cancer), calf circumference (continuous), the Patient-Generated Subjective Global Assessment (PG-SGA) score (reference = 0–1), the KPS score (continuous) and the global QOL score (continuous).
Interaction test, vs. the FAIN: age = 0.097, sex = 0.002, tumor stage <0.001, radical surgery = 0.538, curative chemotherapy = 0.001, pre-albumin = 0.006, handgrip strength = 0.764, NRS2002 = 0.334, length of hospitalization = 0.346, cancer type = 0.044, calf circumference = 0.565, PG-SGA = 0.005, KPS score = 0.013 and global QOL = 0.004.